The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Use of nMoABs for the Treatment of COVID-19 in Patients With HM.
Official Title: Use of Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Patients With Hematological Malignancies (SIE-GIMEMA Study)
Study ID: NCT04932967
Brief Summary: This is a multicenter retrospective, non-interventional observational study to evaluate the efficacy of nMoAbs in HM patients.
Detailed Description: This is a multicenter retrospective, non-interventional observational study. The participating centres will retrospectively review all episodes of SARS-CoV-2 infection occurring in HMs identified at their institutions from February 2020 to May 2021 and treated with nMoAbs, to evaluate their efficacy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Aou Consorziale Policlinico - Uo Ematologia Con Trapianto, Bari, , Italy
Asst Degli Spedali Civili Di Brescia, Brescia, , Italy
Ospedale Valduce - Uos Ematologia, Como, , Italy
Aou Careggi, Firenze, , Italy
Irccs Aou San Martino, Genova, , Italy
Fondazione Irccs "Istituto Nazionale Tumori", Milano, , Italy
Aou Maggiore Della Carità Di Novara, Novara, , Italy
AOU Padova, Padova, , Italy
Aou Pisana - Uo Ematologia Universitaria, Pisa, , Italy
Fondazione Policlinico Universitario Agostino Gemelli-Irccs, Roma, , Italy
Aou "San Giovanni Di Dio E Ruggi D'Aragona" - Salerno - Uoc Ematologia E Trapianti Di Cellule Staminali Emopoietiche, Salerno, , Italy
Aou Senese, Siena, , Italy
Asui Di Udine, Presidio Ou "S. Maria Della Misericordia", Udine, , Italy
Asst Dei Sette Laghi, Ospedale Di Circolo E Fondazione Macchi, Varese, , Italy